Table 1 Results of the base-case analysis.

From: Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer

  1. PF: progression-free. PD w/o BM: progressed disease without brain metastases. PD w/ BM: progressed disease with brain metastases. Costs listed in New Taiwan Dollar (NTD).
  2. Medication cost: include cost from atezolizumab and chemotherapy. non-Medication cost: include cost form surgery, therapy for adverse events, radiotherapy and other health resource cost for SCLC. PD state cost includes subsequent therapy, surgery, radiotherapy and other health resource cost for SCLC.
Back to article page